tiprankstipranks
Enzo Biochem (ENZ)
:ENZ

Enzo Biochem (ENZ) Price & Analysis

Compare
184 Followers

ENZ Stock Chart & Stats


---

Financials

Quarterly

Ownership Overview

12.11%4.54%13.70%65.75%
12.11% Insiders
13.70% Other Institutional Investors
65.75% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

ENZ FAQ

What was Enzo Biochem’s price range in the past 12 months?
Enzo Biochem lowest stock price was $0.41 and its highest was $1.30 in the past 12 months.
    What is Enzo Biochem’s market cap?
    Enzo Biochem’s market cap is $22.35M.
      When is Enzo Biochem’s upcoming earnings report date?
      Enzo Biochem’s upcoming earnings report date is Jun 16, 2025 which is in 80 days.
        How were Enzo Biochem’s earnings last quarter?
        Enzo Biochem released its earnings results on Mar 17, 2025. The company reported -$0.029 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.029.
          Is Enzo Biochem overvalued?
          According to Wall Street analysts Enzo Biochem’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Enzo Biochem pay dividends?
            Enzo Biochem pays a Notavailable dividend of $0.1 which represents an annual dividend yield of N/A. See more information on Enzo Biochem dividends here
              What is Enzo Biochem’s EPS estimate?
              Enzo Biochem’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Enzo Biochem have?
              Enzo Biochem has 52,402,805 shares outstanding.
                What happened to Enzo Biochem’s price movement after its last earnings report?
                Enzo Biochem reported an EPS of -$0.029 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.383%.
                  Which hedge fund is a major shareholder of Enzo Biochem?
                  Currently, no hedge funds are holding shares in ENZ
                  ---

                  Enzo Biochem Stock Smart Score

                  Company Description

                  Enzo Biochem

                  Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Myriad Genetics
                  Orasure Technologies
                  QuidelOrtho
                  CareDx
                  Popular Stocks
                  ---
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis